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Abstract
Background: Epigenetic regulation is an important mechanism leading to cancer initiation and promotion. Histone
acetylation by histone deacetylases (HDACs) represents an important part of it. The development of HDAC
inhibitors has identified the utility of HDACs as a therapeutic target. Little is known about the epigenetic regulation
of vulvar intraepithelial neoplasia (VIN) and vulvar squamous cell cancer (VSCC). In this study, the expression of
class I HDACs (HDAC 1, 2 and 3) was compared in a series of VIN and VSCC tissues.
Methods: A tissue micro array (TMA) with specimens from 106 patients with high-grade VIN and 59 patients with
vulvar cancer was constructed. The expression of HDACs 1, 2 and 3 were analyzed with immunohistochemistry
(IHC). The nuclear expression pattern was evaluated in terms of intensity and percentage of stained nuclei and was
compared between vulvar preinvasive lesions and vulvar cancer.
Results: HDAC 2 expression was significantly higher in VIN than in VSCC (p < 0.001, Fisher’s test). Also, 88.7% (n =
94/106) of VIN samples and only 54.5% (n = 31/57) of VSCC samples were scored at the maximum level.
Conversely, HDAC 3 expression was significantly higher in VSCC (93%, 53/57) compared to VIN (73.6%, 78/106, p =
0.003), whereas only a small difference in the expression of HDAC 1 was found between these two entities of
vulvar neoplasia.
Conclusions: These results suggest that epigenetic regulation plays a considerable role in the transformation of
VIN to invasive vulvar neoplasia.
Keywords: Histone deacetylase, epigenetics, vulvar intraepithelial neoplasia, vulvar squamous cell cancer, tissue
microarray, immunohistochemistry
Background
Invasive vulvar squamous cell carcinomas (VSCC) repre-
sent the fourth most common type of malignant tumor
of the female genital tract in the United States, with an
estimated 3, 580 new cases and 900 deaths in 2009 [1].
Recently, a significant increase of precancerous lesions
and invasive vulvar carcinomas has been observed in
industrialized countries. The incidence of invasive and
vulvar intraepithelial neoplasia (VIN) has risen 2.4% per
year in the U.S. from 1992 to 1998 [2]. A Scandinavian
study describes an increase in VIN incidence more than
4 times from 1973 to 2000 and of 20% for invasive vul-
var cancer [3]. The described increase in incidence is
seen primarily in younger women, whereas in elderly
women, the incidence rates of vulvar cancer have
remained relatively stable over the past few decades.
VIN is most commonly treated by local excision, laser
evaporation, or a combination of both methods, to pre-
serve vulvar function and morphology. The preferred
treatment modality for VSCC is surgery whenever feasi-
ble. Small tumors are treated by wide local excision,
with or without partial or radical vulvectomy, combined
with lymph node staging via sentinel lymph node biopsy
or inguinofemoral lymphadenectomy if lymph node
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metastases are present. For patients with extensively
involved inguinofemoral lymph nodes, radiotherapy of
the pelvis is advantageous. For patients with recurrent
or metastatic disease, irradiation and chemotherapy
offer some benefit; however, response rates are regarded
as low [4,5]. Targeted therapies for VSCC have not yet
been established in clinical practice [6], but given the
low benefit of conventional chemotherapies, novel sys-
temic treatment modalities are urgently needed for
these patients.
Epigenetics characterize the hereditary changes in the
pattern of gene expression that are not due to changes
in DNA sequence. Genetics and epigenetics interact at
all stages of cancer development. Epigenetic alterations
in mammalian genomes fall into two main categories:
DNA methylation and histone modification. Histones
are strongly alkaline proteins that are able to package
the DNA and condense it into structural units called
nucleosomes. Acetylation and deacetylation of histones
are performed by histone acetyltransferase (HATs) and
histone deacetylases (HDACs), respectively. HDACs
increase the affinity of histone complexes to DNA. The
chromatin is thereby more condensed and transcription-
ally repressed [7-9].
Additionally HDACs can modify proteins other than
histones, such as transcription factors (e.g. p53, E2F,
pRb). Acetylation can also affect protein stability and
protein-protein interactions. Therefore, HDACs are
emerging as important regulators of cell growth, differen-
tiation, and apoptosis [10,11]. There are at least eighteen
deacetylase enzymes known in human cells, categorized
into four classes: class I (HDAC 1, 2, 3, 8), class II
(HDAC 4, 5, 6, 7, 9, 10), class III (SIRT 1-7) and class IV
(HDAC 11). HDAC1 and HDAC2 are one of the best-
characterized HDACs. However, the isoenzyme-specific
biological functions of HDACs are still mostly unknown
[8]. It has been postulated that dysregulated function of
HDACs leads to cancer formation and development [11].
Altered HDAC expression is observed in a variety of can-
cer types, such as prostate adenocarcinoma [12], gastric
carcinoma [13], colorectal carcinoma [14], cervical dys-
plasia and endometrial stromal sarcoma [15]. In vulvar
intraepithelial neoplasia and vulvar cancer, no data on
HDAC expression has been published.
The aim of this study was to analyze the expression of
the class I HDACs 1, 2 and 3 by immunohistochemistry
in a series of VIN and VSCC samples using the tissue
microarray technique and to correlate the finding with
the clinicopathological features of the patients.
Methods
Patient characteristics
One-hundred-six patients diagnosed with high-grade
VIN and 59 patients with VSCC between 1993 and 2006
at the Institute of Pathology, University Hospital Zurich
were included in this study. The study was approved by
the local ethics committee (ref. number StV 08/2006).
Histological diagnosis was established according to the
guidelines of the International Society for the Study of
Vulvovaginal Disease (ISSVD) [16].
Clinical data were available for 158 of the 165 cases.
Follow-up data of at least six months were available for
74 of the 106 patients with VIN and 25 of the 59
patients with VSCC. Mean follow-up time was 67.8
months (SD ± 41.8, range 8 - 169 months) and 50.6
months (SD ± 42.7, range 6 - 149 months) in patients
with VIN and VSCCs, respectively. Table 1 shows the
patient’s age and p16 status in VIN and VSCC. Table 2
shows the clinicopathological data of the patients with
VSCC included in the study.
Tissue Microarray construction
Two tissue microarrays (TMA), one for the VIN and
one for the VSCC cases, were constructed using a semi-
automatic tissue arrayer (Beecher Instruments, Wood-
land, USA) as previously described [17]. Areas involving
vulvar cancer or VIN were marked on hematoxylin/
eosin-stained sections. Cylindrical cores 0.6 mm in dia-
meter were punched out of the corresponding paraffin
embedded block and inserted into a recipient block.
Two different spots from each tumor were punched out.
Immunohistochemistry
TMA sections (2.5 μm) were transferred to glass slides,
followed by immunohistochemical analysis according to
the Ventana automat protocols. The following antibo-
dies were used: polyclonal rabbit IgG antibody against
HDAC 1 (dilution 1:2, Abcam Limited, clone: ab15316,
UK-CB4 0FL Cambridge, United Kingdom), monoclonal
mouse IgG antibody against HDAC 2 (dilution 1:1000,
Abcam Limited, clone: ab12169, UK-CB4 0FL Cam-
bridge, United Kingdom) and monoclonal mouse IgG
antibody against HDAC 3 (dilution 1:500, Becton Dick-
inson, clone: 611125, NJ-07417 Franklin Lakes, United
States of America).
Additionally, immunohistochemical staining with p16
(dilution 1:200, Santa Cruz Biotechnology, clone: sc-
56330, CA-95060 Santa Cruz, United States of America)
Table 1 Patients’ age and p16 status in different
diagnostic groups
p16 n age mean SD range
VIN pos 93 49.1 ± 14.6 22 - 89
Neg 13 74.3 ± 14.9 35 - 93
VSCC Pos 31 61.8 ± 14.3 37 - 90
Neg 26 77.3 ± 10.3 53 - 93
Mean age, standard deviation (SD) and range are given in years.
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and Ki-67 (dilution 1:20, DAKO, clone: M7240, DK-
2600 Glostrup, Denmark) was performed.
P16, a tumor suppressor gene, inhibits cyclin depen-
dent kinase 4 (CDK4), 6 (CDK6) and retinoblastoma pro-
tein (pRb) and subsequently blocks the passage from G1
into S phase [18]. Human papilloma virus (HPV) inacti-
vates p53 and pRb with its E6 and E7 oncogenic proteins
after infection of epithelial cells, which results in an over-
expression of p16 versus a negative feedback control of
pRb [19,20]. Therefore, p16 expression has been estab-
lished as a surrogate marker for HPV infection and is
used for pathomorphological investigation [21-23]. Ki-67
(Mib-1) is expressed during cellular proliferation and,
therefore, is used as a marker to determine the growth
fraction in tissue samples (proliferation index) [24].
Immunohistochemical staining of HDAC isoforms was
scored by applying a semiquantitative immunoreactivity
scoring system (IRS). Therefore the percentage of positive
cells was categorized as none (0), less then 10% of the cells
(1), 10-50% of the cells (2), 51-80% of the cells (3), and
more then 80% of the cells (4). The intensity was graded
as absent (0), weakly positive (1+), moderately positive (2
+) or strongly positive (3+). The IRS score results from
multiplying the area-score with the intensity of
immunoreactivity, as described elsewhere [25]. It ranges
from 0 to 12. Nuclear staining of HDACs was considered
positive, whereas cytoplasmic staining was regarded as
nonspecific. Both TMAs were scored by two observers (N.
S. & R.C.) who were blinded to the clinicopathological
information of each sample. The two cores of each indivi-
dual tumor were scored separately, and the mean score of
the two twin tissue cores was attributed to a single patient.
To assess correlations and associations between
expression of HDACs and clinicopathological para-
meters, Spearman’s rho (bivariate correlation analysis),
Fisher’s exact test and c-square tests were applied,
where appropriate. p-values of < 0.05 were considered
significant. SPSS 18.0 package software (SPSS Inc., Chi-
cago/Illinois, USA) was used.
Results
HDAC expression in VIN and VSCC
Nuclear HDAC 1, 2 and 3 staining could be evaluated in
163 of 165 cases (98.8%). In 9 cases out of 163 (5.5%), only
one of both tissue cores could be analyzed. In the non-eva-
luable cases, the cores lacked sufficient epithelial cells.
In VIN, mean IRS-scores of HDAC 1, HDAC 2 and
HDAC 3 were 9.99, 11.56 and 10.88, and they were
9.83, 9.75 and 11.72 in VSCC, respectively. The median
IRS-score was 12 for every HDAC isoform in both VIN
as well as VSCC. Hence, the cut-off point for statistical
analysis was taken at a score level of 12. Results were,
therefore, dichotomized into a “HDAC high” group
(IRS = 12) and a “HDAC low” group (IRS < 12).
The Association of HDAC 1, 2 and 3 expressions with
clinicopathological parameters is summarized in Table 3.
HDAC 2 expression was significantly higher in VIN than
in VSCC (p < 0.001, Fisher’s test). 88.7% (n = 94/106) of
VIN samples were scored at the maximum level (IRS 12);
vulvar cancer samples only in 54.5% (n = 31/57). Conver-
sely, HDAC 3 expression was significantly higher in
VSCC (93%, 53/57) compared to VIN (73.6%, 78/106),
and p = 0.003. No significant distribution was found for
HDAC 1 within vulvar neoplasias. In fact, the percentage
of tissue samples with high HDAC 1 protein expression
is almost equal between VIN (57.5%) and VSCC (56.1%).
The reciprocal expression pattern of HDAC 2 and 3 is
illustrated in representative tissue examples in Figure 1
and graphically visualized in Figure 2.
In a bivariate correlation analysis, IRS scores of the
three HDAC isoforms correlated significantly with each
other in VIN samples, whereas no correlation between
isoform 2 and 3 was found in VSCC.
Correlation of HDAC expression with clinicopathological
parameters
There was a moderate correlation between HDAC 2
and pT stage in VSCC (p = 0.009), whereas no
Table 2 Clinicopathological features of patients with
VSCC
n percentage
T stage
1 22 37.3%
2 24 40.7%
3 9 15.3%
4 0 0.0%
Not available 4 6.8%
Lymphe node metasases
None 24 40.7%
Unilateral 14 23.7%
Bilateral 6 10.2%
Not available 15 25.4%
Distant metastases
No 28 47.5%
Yes 1 1.7%
Not available 30 50.8%
FIGO
I 16 27.1%
II 12 20.3%
III 13 22.1%
IV 5 9.5%
Not available 13 22.0%
Tumor differentiation
Well 13 22.0%
Moderate 30 50.8%
Poor 16 27.1%
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significant association between tumor size and high
HDAC 2 expression was observed. A high proliferation
index (Ki-67 area) correlated with high HDAC 1 (p =
0.008, cc = 0.21) and HDAC 2 (p < 0.001, cc = 0.36)
expression. Using cut-off levels of 10%, this correlation
was confirmed (Table 3). Similar to this findings,
applying a cut-off level of 25% results in a significant
associations between Ki-67 and HDAC 1 in VIN (p =
0.012) and Ki-67 and HDAC 2 in the VSCC group (p
= 0.035).
In the grouped analyses, no significant association
between p16 positivity and patient age with HDAC
expression was observed (Table 3). In fact, almost equal
frequencies were found between p16 and HDAC 1 as
well as between patient age and HDAC 2. There was no
significant association between tumor size (pT) and high
HDAC 2 expression.
Discussion
This study shows that class I HDACs are highly
expressed in the majority of VIN and VSCC; however,
the expression patterns differ between VIN and VSCC.
High HDAC-2 protein expression is found more often
in VIN, and high HDAC-3 protein expression is found
more often in VSCC. These two types of HDACs are
neither associated with patient age nor with level of p16
expression. Therefore, the observed differences are not
explained by the difference of the average age or fre-
quency of p16 positivity in VIN and VSCC. The immu-
nohistochemical staining showed high intensity in the
majority of tissue samples, and negative results were not
found. HDAC 3 was the most intensely expressed iso-
form of all three class I HDACs.
Based on the expression pattern of histone deacetylat-
ing proteins, we hypothesized that epigenetic regulation
plays a major role in the pathogenesis of invasive vulvar
cancer, as has been demonstrated for several other
malignancies [12-15]. The transformation of non-inva-
sive to invasive vulvar neoplasia may be promoted by
epigenetic regulation. To our knowledge, this report is
the first on class I HDAC expression in vulvar cancer or
vulvar intraepithelial neoplasia.
Table 3 Association of HDACs with clinicopathological parameters
Total HDAC1 low HDAC1 high p HDAC2 low HDAC2 high p HDAC3 low HDAC3 high p
All Cases 163 70 (42.9%) 93 (57.1%) – 38 (23.3%) 125 (76.7%) – 32 (19.6%) 131 (80.4%) –
VIN 106 45 (42.5%) 61 (57.5%) 0.87 12 (11.3%) 94 (88.7%) < 0.001 28 (26.4%) 78 (73.6%) 0.003
VSCC 57 25 (43.9% 32 (56.1%) 26 (45.6%) 31 (54.4%) 4 (7.0%) 53 (93.0%)
p16 neg 39 17 (43.6%) 22 (56.4%) 1.00 10 (25.6%) 29 (74.4%) 0.67 4 (10.3%) 35 (89.7%) 0.109
p16 pos 124 53 (42.7%) 71 (57.3%) 28 (22.6%) 96 (77.4%) 28 (22.6%) 96 (77.4%)
Age ≤ 60 93 41 (44.1%) 52 (55.9%) 0.752 22 (23.7%) 71 (76.3%) 1.00 21 (22.6%) 72 (77.4%) 0.322
Age > 60 70 29 (41.4%) 41 (58.6%) 16 (22.9%) 54 (77.1%) 11 (15.7%) 59 (84.3%)
VSCC°
pT1 20 7 (35.0%) 13 (65.0%) 0.556* 5 (25.0%) 15 (75.0%) 0.057* 1 (5.0%) 19 (95.0%) 0.831*
pT2 24 11 (45.8%) 13 (54.2%) 13 (54.2%) 11 (45.8%) 2 (8.3%) 22 (91.7%)
pT3 9 5 (55.6%) 4 (44.4%) 6 (66.7%) 3 (33.3%) 1 (11.1%) 8 (88.9%)
pN0 23 9 (39.1%) 14 (60.9%) 0.763 9 (39.1%) 14 (60.9%) 0.366 1 (4.3%) 22 (95.7%) 1.00
pN1/2 20 9 (45.0%) 11 (55.0%) 11 (55.0%) 9 (45.0%) 1 (5.0%) 19 (95.0%)
G1 12 5 (41.7%) 7 (58.3%) 0.009* 7 (58.3%) 5 (41.7%) 0.602* 1 (8.3%) 11 (91.7%) 0.513*
G2 29 8 (27.6%) 21 (72.4%) 12 (41.4%) 17 (58.6%) 1 (3.4%) 28 (96.6%)
G3 16 12 (75%) 4 (25.0%) 7 (43.8%) 9 (56.3%) 2 (12.5%) 14 (87.5%)
VIN
Ki-67 ≤ 10% 11 9 (81%) 2 (18.2%) 0.008 3 (27.3%) 8 (72.7%) 0.109 4 (36.4%) 7 (63.6%) 0.476
Ki-67 > 10% 95 36 (37.9%) 59 (62.1%) 9 (9.5%) 86 (90.5%) 24 (25.3%) 71 (74.7%)
VSCC
Ki-67 ≤ 10% 19 8 (42.1%) 11 (57.9%) 1.00 14 (73.7%) 5 (26.3%) 0.004 2 (10.5%) 17 (89.5%) 0.594
Ki-67 > 10% 38 17 (44.7%) 21 (55.3%) 12 (31.6%) 26 (68.4%) 2 (5.3%) 36 (94.7%)
HDAC immunoreactivity score (IRS) has been dichotomized in two groups; HDAC 1 to 3 “high” represent tissue samples with a IRS of 12, HDAC 1 to 3 “low”, a IRS
less than 12. Clinicopathological parameters investigated in this study are listed in the first column; Vulvar intraepithelial neoplasia (VIN), vulvar squamous cell
cancer (VSCC); p-16 as a surrogate marker for human papilloma virus (HPV) infection as described before [21-23]; patient younger than 60 years (Age ≤ 60),
patient equal or elder than 60 years (Age > 60); related pTNM-stage and tissue differentiation (G1 to G3) in VSCC. Nuclear Ki-67 protein is a marker for cell
proliferation. “Ki-67 ≤ 10%” means that 10 percent or less of the cells are proliferating.
Percentages in parentheses are according to the total number of samples in the first column. P-values result from the association of HDAC low and high groups
to one parameter, such as tissue type VIN versus VSCC. Where not specified, Fisher’s exact test was used to calculate p-values. P-values labeled by * have been
obtained by c-square test. For a facilitated reading, corresponding data to p-values are in one grid each.
° T-stage: 6 cases missing at all, no cases of pT4; N-stage: 15 cases missing; M-stage: not shown, 30 cases with no investigation and or data missing.
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Figure 1 Representative tissue samples of one VIN microarray core (A1, B1, C1, D1) and one VSCC microarray core (A2, B2, C2, D2)
stained with hematoxylin/eosin (HE) (A1 and A2) and nuclear immunohistochemical reaction with class I HDAC antibodies: HDAC 1
(B1 and B2), HDAC 2 (C1 and C2) and HDAC 3 (D1 and D2); Magnification × 200. Under each immunohistochemical stain, the percentage
of positive epithelial cells within the tissue core (area), the intensity of immunoreactions (intens.) and the immunoreactivity score (IRS) are
indicated.
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P16 has been proposed as a surrogate marker for HPV
associated neoplasia [21-23]. We found no difference
between class I HDAC expression in p16-negative or
p16-positive tumor tissue. Therefore, the regulation of
gene expression by HDACs seems to be independent of
HPV infection.
One mechanism by which HDACs appear to stimulate
tumor cell growth is through the repression of the
tumor suppressor gene, p21 [26]. In this study, high
expression of HDAC 1 in VIN and high expression of
HDAC 2 in VSCC were associated with increased cell
proliferation, as defined by Ki-67. This result supports
previous findings in other tumor types, such as prostate
cancer and colorectal cancer [27,28]. With the exception
of the significant correlation of HADC 1 and 2 with the
proliferation marker Ki-67, no relation was found
between HDAC expression and clinicopathological fea-
tures. Still, the utility of these results must be
considered carefully because of the lack of a full clinical
data set.
The epigenetic regulation of HDACs has recently been
explored as a therapeutic target by the discovery and
development of HDAC-inhibitors (HDACi). In-vitro data
suggest that HDACi induce cell cycle arrest, differentia-
tion, and apoptosis [15,29-32]. The antitumor effects of
HDACi emphasize the important role of HDACs in can-
cer development. However, HDACi affects the activity of
several enzymes, and it is difficult to identify the parti-
cular functions of different HDAC isoforms involved in
cancerogenesis. Several HDACi are currently under clin-
ical investigation involving various hematological malig-
nancies and solid tumors, of which vorinostat has
already been approved for the systemic treatment of
cutaneous T cell lymphoma [33]. Particularly, in oral
squamous cell cancer, there are different phase I and II
trials using HDAC-i as a monotherapy or in
Figure 2 HDACs immunoreactivity score (IRS) in VIN and vulvar cancer tissue. The mean IRS is represented by a circle, and the 95%
confidence interval is represented by an error bar. The confidence intervals of VIN and VSCC in HDAC 2 and HDAC 3 do not overlap in contrast
to that of HDAC 1.
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combination with other agents. This treatment method
is of interest regarding VSCC [34-37].
Conclusions
In summary, HDACs, the targets of HDACi, are highly
expressed in the majority of VIN and VSCC and show a
different expression pattern among these two tissue
types irrespective of the HPV-related etiology. Investiga-
tions of HDAC-i for the topical or systemic treatment
of VIN and VSCC are warranted.
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